Review Compares Metoclopramide to Domperidone for Gastroparesis
For those who want to gain an in-depth knowledge of gastroparesis, Professors A. Patrick and O. Epstein have published a 17-page review of the current literature on gastroparesis and gastroparesis treatment in the journal Alimentary Pharmacology and Therapeutics.
The review concludes, "Despite a significant progress in the past decade, further controlled trials are required into the therapeutic options available for treating this intriguing condition."
The authors note that "there are no adequately powered controlled trials to support a particular drug regimen." They compared the use of metoclopramide and domperidone for gastroparesis (two commonly prescribed gastroparesis medications - brand name Reglan and brand name Motilium), saying:
Domperidone is a benzimidazole derivative and is a specific dopamine antagonist with similar physiological effects on the upper gastrointestinal tract as metoclopramide. The blood-brain barrier is relatively impermeable to domperidone and consequently, it has fewer central side effects, whilst still offering some antiemetic effect. Controlled trials have shown efficacy in gastroparesis and in diabetics; the effect is similar to metoclopramide but with fewer side effects.
To read the entire gastroparesis literature review online, >Click Here.<
Leave your comment:
Your email address will not be published. Required fields are marked with *.